Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer.

International journal of cancer - 1 Dec 2012

Ryan Bríd M, Calhoun Kara M, Pine Sharon R, Bowman Elise D, Robles Ana I, Ambs Stefan, Harris Curtis C

Abstract excerpt

Conflicting reports exist regarding the contribution of SNP309 in MDM2 to cancer risk. Recently, SNP285 was shown to act as an antagonist to SNP309 by overriding the effect of SNP309 on SP1-mediated transcription. Moreover, SNP285 modified the relationship between SNP309 and risk of breast, ovarian and endometrial cancer. We assessed whether SNP285 confounded the effect of SNP309 in lung cancer in a cohort of 720...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alleles
Share to Case-Control Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Genetic Predisposition to Disease

Share to Lung Neoplasms

Share to Polymorphism, Single Nucleotide

Share to Proto-Oncogene Proteins c-mdm2

Source

Open in PubMed Open full text

Identifiers

PMID: 22487911
DOI: 10.1002/ijc.27573
PMCID: PMC3414691

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer.PMID 22487911Read ↗

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.Semantic proximity Read ↗

MDM2 SNP309 and SNP354 are not associated with lung cancer risk.Semantic proximity Read ↗

The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.Semantic proximity Read ↗

Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk.Semantic proximity Read ↗

Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649).Semantic proximity Read ↗

SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.Semantic proximity Read ↗

MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer.Semantic proximity Read ↗

MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk.Semantic proximity Read ↗

Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls.Semantic proximity Read ↗

Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis.Semantic proximity Read ↗

MDM2 SNP309 and cancer risk: a combined analysis.Semantic proximity Read ↗

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.